VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
WHWKWhitehawk Therapeutics Inc$4.16$206M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksWHWKP/E History

WHWK logoWhitehawk Therapeutics Inc (WHWK) P/E Ratio History

Deep Value

Trading at -12.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025

Current P/E (TTM)
-12.6x
-227% vs 5Y avg
5Y Avg P/E
9.9x
Median 11.1x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-12.6x
Min5.1xMedian11.1xMax13.6x
TTM EPS$-0.30
Price$4.16
Earnings YieldN/A
EPS Growth (1Y)86.0%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 13, 2026, Whitehawk Therapeutics Inc (WHWK) trades at a price-to-earnings ratio of -12.6x, with a stock price of $4.16 and trailing twelve-month earnings per share of $-0.30.

The current P/E is 227% below its 5-year average of 9.9x. Over the past five years, WHWK's P/E has ranged from a low of 5.1x to a high of 13.6x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.9x, WHWK trades at a 155% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 183.0x.

Relative to the broader market, WHWK trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our WHWK DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

WHWK Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-12.6vs22.9
-155%
Below Sector
vs. S&P 500
-12.6vs25.1
-150%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 86% EPS growth (1Y)

WHWK P/E vs Peers

Oncology Therapeutics Developers peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ACAD logoACADACADIA Pharmaceuticals Inc.
$4B9.2-+68%
INVA logoINVAInnoviva, Inc.
$2B6.9Lowest0.67+817%Best
IQV logoIQVIQVIA Holdings Inc.
$31B23.10.57Best+5%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

WHWK Historical P/E Data (2025–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$2.42$0.475.1x-48%
FY2025 Q3-$1.90$0.1413.6x+36%
FY2025 Q1Mar 31 2025$1.78$0.1611.1x+12%

Average P/E for displayed period: 9.9x

Export Data

What if you invested $1,000 in WHWK back in 2025?

Total return with dividends reinvested · 1+ years of data

Calculate Returns

How much would $100/month in WHWK be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is WHWK Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

WHWK vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

WHWK — Frequently Asked Questions

Quick answers to the most common questions about buying WHWK stock.

What is WHWK's P/E ratio?

Whitehawk Therapeutics Inc (WHWK) trailing twelve-month P/E ratio is -12.6x, based on TTM diluted EPS of $-0.30. The 5-year average P/E is 9.9x and the historical range spans 5.1x to 13.6x.

Is WHWK stock overvalued or undervalued?

WHWK trades at -12.6x P/E, below its 5-year average of 9.9x. At the 0th percentile of its historical range (5.1x–13.6x), the stock is priced at a discount to its own history.

Is WHWK stock expensive?

No, WHWK is not expensive on a historical basis. The current P/E of -12.6x is below the 5-year average of 9.9x and sits at the 0th percentile of its valuation range.

What is WHWK's historical P/E range?

Over the past 5 years, WHWK's P/E ratio has ranged from 5.1x to 13.6x, with a median of 11.1x and an average of 9.9x. The current P/E of -12.6x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.

How does WHWK's P/E compare to the S&P 500?

WHWK trades at -12.6x P/E versus the S&P 500 median of 25.1x. The 150% discount to the market suggests lower growth expectations or perceived higher risk.

How does WHWK's valuation compare to Healthcare peers?

Whitehawk Therapeutics Inc P/E of -12.6x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is WHWK's PEG ratio?

WHWK PEG ratio is N/A, based on a P/E of -12.6x and EPS growth of 86.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is WHWK's earnings yield?

WHWK earnings yield is N/A, the inverse of its -12.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

WHWK P/E Ratio History (2025–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current5.1x
Period Avg9.9x
Range5.1x - 13.6x
Change-54%
3 quartersMar 31, 2025 - Dec 31, 2025